New treatments for eye injuries caused by chloropicrin exposure
Treatment strategies for ocular toxicity from chloropicrin
This study is looking at how a chemical called chloropicrin can hurt the eyes and is testing ways to help protect the eyes from that damage, which could lead to new treatments for people who have experienced eye injuries from harmful substances.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10463565 on NIH RePORTER |
What this research studies
This research investigates how exposure to chloropicrin, a chemical that can cause severe eye injuries, affects the cornea and explores potential treatments to mitigate these injuries. The study focuses on understanding the mechanisms of damage and aims to activate the Nrf2 pathway, which helps protect cells from oxidative stress and inflammation. By using specialized mouse models, researchers will assess the effectiveness of Nrf2 activators in reducing both immediate and long-term ocular damage. This approach could lead to new therapies for eye injuries caused by various toxic substances.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced eye injuries from chloropicrin or similar toxic chemicals.
Not a fit: Patients with ocular injuries not related to chemical exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from ocular injuries due to chemical exposure.
How similar studies have performed: Previous research has shown promise in activating the Nrf2 pathway for treating oxidative stress-related ocular conditions, suggesting potential success for this approach.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Tewari-Singh, Neera — Michigan State University
- Study coordinator: Tewari-Singh, Neera
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.